Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer
File(s)Tokaca Revised Manuscript - Final Version.docx (741.47 KB)
Accepted version
Author(s)
Type
Journal Article
Abstract
Small cell transformation is a rare but well recognised mechanism of acquired resistance to EGFR-TKI therapy in EGFR-mutated NSCLC, but optimal drug therapy thereof is unknown. Nivolumab has demonstrated activity in relapsed de novo small cell lung cancer in early phase trials. Here, we report a case of transformed EGFR-mutant SCLC treated with nivolumab with no benefit.
Date Issued
2017-07-11
Date Acceptance
2017-07-09
Citation
Lung Cancer, 2017, 111, pp.65-68
ISSN
0169-5002
Publisher
Elsevier
Start Page
65
End Page
68
Journal / Book Title
Lung Cancer
Volume
111
Copyright Statement
© 2017 Elsevier B.V. All rights reserved. This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/
Subjects
Science & Technology
Life Sciences & Biomedicine
Oncology
Respiratory System
NSCLC
Adenocarcinoma
EGFR
Small cell lung cancer
Transformation
Nivolumab
RESISTANCE MECHANISM
DOCETAXEL
Publication Status
Published